Evaluation of Myostatin Protein in Serum of Cardiac Patients
Abstract
In order to assess the significance of myostatin protein with some biochemical parameters in the blood serum of myocardial infarction and atherosclerosis patients. The study included 60 samples of heart patients (30 samples of myocardial infarction patients and 30 samples of patients with atherosclerosis) whose ages ranged from 35 to 65 years, in addition to 30 samples of healthy people of the same age group. Results revealed a marked rise in the level of myostatin protein in the myocardial infarction and atherosclerosis patients in comparison to healthy group, and rise in troponin protein in myocardial infarction patients. According to the findings, total cholesterol, triglycerides, low-density lipoproteins, and very-low-density lipoproteins were all significantly higher in the two patients groups than in healthy group, whereas high-density lipoprotein levels were significantly lower in both patients groups. The results indicated that calcium level had significantly decreased in myocardial infarction patients, but no change in phosphate level between groups. The findings revealed a significantly lower of glutathione and a significantly higher of malondialdehyde in the two patients groups as compared to the healthy group. In conclusion, the obtained data were directly aligned with the study hypothesis, showing significant elevation of myostatin and associated biochemical changes relevant to the pathophysiology of myocardial infarction and atherosclerosis, thus supporting the study objective. Results suggest myostatin as a potential supplementary biomarker and highlight useful biochemical alterations for patient assessment; however, lack of established diagnostic cut-offs, limited routine availability of myostatin testing, and small sample size may limit immediate clinical application.
Keywords
Myostatin, Troponin, Lipids profile, Myocardial infarction atherosclerosis
References
- [1] Bachmann J. M., Willis B. L., Ayers C. R., Khera A., Berry J. D., Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study, Circulation, 125(25) (2012) 3092-3098.
- [2] Aiello D., Patel K., Lasagna E., The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals, Anim. Genet., 49(6) (2018) 505-519.
- [3] Liu Y., Xu J., Wu M., Xu Y., Li M., Sun D., Yang X., Circulating myostatin is associated with insulin resistance in patients with type 2 diabetes mellitus, J. Diabetes Res., 2021 (2021) 5579273.
- [4] Zhang C., McFarlane C., Lokireddy S., Bonala S., Ge X., Masuda S., Sharma M., Myostatin-deficient mice exhibit reduced insulin resistance through activating AMP-activated protein kinase, Diabetologia, 63(3) (2020) 580-593.
- [5] Zhou Y., Hellberg M., Svensson P., Höglund P., Clyne N., Jacobson S. H., Association between circulating myostatin, body composition and muscle strength in patients with chronic kidney disease, Nephrol. Dial. Transplant., 34(3) (2019) 514-520.
- [6] Camporez J. P., Petersen M. C., Abudukadier A., Moreira G. V., Jurczak M. J., Friedman G., Shulman G. I., Role of skeletal muscle myostatin in cancer cachexia, J. Clin. Invest., 130(4) (2020) 1704-1716.
- [7] Morissette M. R., Cook S. A., Foo S., McKoy G., Ashida N., Novikov M., Rosenthal N., Myostatin regulates cardiomyocyte growth through modulation of Akt signaling, J. Biol. Chem., 291(4) (2016) 1745-1754.
- [8] Biesemann N., Mendler L., Wietelmann A., Hermann S., Schäfers M., Krüger M., Bisping E., Myostatin regulates energy homeostasis in the heart and prevents heart failure, Circ. Res., 115(3) (2014) 296-310.
- [9] Shah J., Walker’s A., Quantitative determination of MDA, Biochem. Biophys Acta, 11 (1989) 207-11.
- [10] Sedlak J., Lindsay R. H., Analytical biochemistry, (1968) 192. cited by Al-Zamely O. M., Al-Nimer M. S., Muslih R. K., Detection the level of peroxynitrite and related with antioxidants status in the serum of patient with acute, (2001).